

Drug Policy

Policy:	20210302	Initial Effective Date: Annual Review Date: 02/15/2024 Last Revised Date: 02/15/2024
Code(s):	HCPCS J3490	
SUBJECT:	Cabenuva® (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension)	

Subject to Site of Care

Prior approval is required for some or all procedure codes listed in this Corporate Drug Policy.

POLICY STATEMENT

This policy involves the use of Cabenuva. Prior authorization is recommended for pharmacy and medical benefit coverage of Cabenuva. Approval is recommended for those who meet the conditions of coverage in the **Criteria, Dosing (medical benefit requests only), Initial/Extended Approval, Duration of Therapy, and Labs/Diagnostics** for the diagnosis provided. **Waste Management** applies for all covered conditions that are administered by a healthcare professional. **Conditions Not Recommended for Approval** are listed following the recommended authorization criteria and Waste Management section. Requests for uses not listed in this policy will be reviewed for evidence of efficacy and for medical necessity on a case-by-case basis.

Initial and renewal requests for the medication(s) listed in this policy are subject to site of care management. When billed under the medical benefit, administration of the medication will be restricted to a non-hospital facility-based location (i.e., home infusion provider, provider’s office, free-standing ambulatory infusion center) unless the member meets the site of care exception criteria. To view the exception criteria and a list of medications subject to site of care management please [click here](#).

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Cabenuva is recommended in those who meet the following criteria:

FDA-Approved Indications

- 1. Human Immunodeficiency Virus (HIV)-1, Treatment.** Approve for the duration below if the patient meets ONE of the following conditions (A or B):
 - A) **Initial Therapy:** Approve if the patient meets all the following (i, ii, iii, iv, and v):
 - i. Patient is \geq 12 years of age; AND
 - ii. Patient weighs \geq 35kg; AND
 - iii. Patient has HIV-1 RNA < 50 copies/mL (viral suppression) **[documentation required]**; AND
 - iv. Prior to initiating Cabenuva or 1 month lead-in with Vocabria, the patient was treated with a stable regimen (\geq 3 months) of antiretrovirals for HIV-1 **[documentation required]**; AND

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

- v. The medication is prescribed by or in consultation with a physician who specializes in the treatment of HIV infection.
- B) Patient is Currently Receiving Cabenuva: Approve if the patient meets all the following (i):
 - i. Patient has HIV-1 RNA < 50 copies/mL (viral suppression) **[documentation required]**.

Dosing in Cabenuva. *Dosing must meet the following [medical benefit only]:*

The recommended initial injection doses of CABENUVA in adults are a single 600-mg (3-mL) gluteal intramuscular injection of cabotegravir and a single 900-mg (3-mL) gluteal intramuscular injection of rilpivirine. Administer cabotegravir and rilpivirine at separate gluteal injection sites (on opposite sides or 2 cm apart) during the same visit. Continuation injections should be initiated a month after the initiation injections.

Initial Approval/ Extended Approval.

- A) *Initial Approval: 1 year (365 days)*
- B) *Extended Approval: 1 year (365 days)*

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Cabenuva has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval).

1. **Pre-Exposure Prophylaxis (PrEP) of Human Immunodeficiency Virus (HIV)-1 Infection.** Cabenuva is not indicated for the prevention of HIV.
2. **Co-administration with Antiretrovirals for Human Immunodeficiency Virus.** Because Cabenuva is a complete regimen, co-administration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.¹
3. **Human Immunodeficiency Virus (HIV)-2 Infection.** Cabenuva is not indicated in patients with HIV-2 infection.¹ The Department of Health and Human Services guidelines further note that HIV-2 is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors, therefore, Cabenuva is not recommended for people with HIV-2.⁵
4. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

Documentation Requirements:

The Company reserves the right to request additional documentation as part of its coverage determination process. The Company may deny reimbursement when it has determined that the drug provided or services performed were not medically necessary, investigational or experimental, not within the scope of benefits afforded to the member and/or a

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

pattern of billing or other practice has been found to be either inappropriate or excessive. Additional documentation supporting medical necessity for the services provided must be made available upon request to the Company. Documentation requested may include patient records, test results and/or credentials of the provider ordering or performing a service. The Company also reserves the right to modify, revise, change, apply and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

REFERENCES

1. Cabenuva® injection [prescribing information]. Research Triangle Park, NJ: ViiV Healthcare/GlaxoSmithKline; January 2021.
2. Orkin C, Arasteh K, Hernandez-Mora G, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. *N Engl J Med.* 2020;382:1124-1135.
3. Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. *N Engl J Med.* 2020; 382;12:1112-1123.
4. Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults. 2020 recommendations of the International Antiviral Society-USA Panel. *JAMA.* 2020;324(16):1651-1669.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>. Updated December 18, 2019. Accessed January 27, 2021.
6. Orkin C, Bernal E, Tan DHS, et al. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: Week 124 results of the open-label phase 3 FLAIR study. *Lancet HIV.* 2021;11:e668-e678.

Prior approval is required for HCPCS Codes J3490

†When *unclassified drugs (J3490)* is determined to be Cabenuva

Edits and Denials:

Prior approval: Prior approval is required for Cabenuva (**HCPCS Codes J3490**). Requests for prior approval will be authorized by a nurse reviewer if submitted documentation meets criteria outlined within the Corporate Medical Policy.

Requests for prior approval will be forwarded to a qualified physician reviewer if submitted documentation does not meet criteria outlined within Corporate Medical Policy.

TOPPS: Claims received with **HCPCS Codes J3490** will pend with **Remark Code M3M or M4M** and will be adjudicated in accordance with the Corporate Medical Policy.

Liability: A participating provider will be required to write off charges denied as not medically necessary.

Drug Policy

HCPCS Code(s):	
J3490	Unclassified drugs

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>